Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

A differentiation antigen commonly expressed on melanoma cells, gp100 is the target of infiltrating T cells. We conducted a phase I randomized cross-over trial of melanoma patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 ...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan, Jianda, Ku, Geoffrey Y., Gallardo, Humilidad F., Orlandi, Francesca, Manukian, Gregor, Rasalan, Teresa S., Xu, Yinyan, Li, Hao, Vyas, Shachi, Mu, Zhenyu, Chapman, Paul B., Krown, Susan E., Panageas, Katherine, Terzulli, Stephanie L., Old, Lloyd J., Houghton, Alan N., Wolchok, Jedd D.
Format: Artigo
Language:Inglês
Published: Academy of Cancer Immunology 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2888533/
https://ncbi.nlm.nih.gov/pubmed/19496531
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items